Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu

Zogenix, GW Pharma Discovering Epilepsy Treatments

Z-ARCHIVE-Cannabis Patent Forecast®

April 16, 2020

Zogenix is searching for and developing treatments for rare diseases such as those that cause different forms of epilepsy. Just this week, Zogenix received a patent (US Pat. No. 10,603,290) for a treatment for seizures which uses fenfluramine in combination with cannabidiol to counter a metabolism pathway that creates norfenfluramine having undesired side effects. Cannabidiol has been combined with other drugs, such as botox, to downplay some of the side effects of the primary drug.

Zogenix is not alone in the cannabis for epilepsy space. In fact, as you may have already guessed, GW Pharmaceuticals was also listed this week for a grant for patent 10,603,288. Patent ‘288 claims a CBD composition, also in the presence of another epilepsy treating drug, for "treatment-resistant epilepsy".

GW Pharmaceuticals is the leading patent assignee in the cannabis sector. Take a custom look at the cannabis sector IP landscape at MagicNumberIP.com with a subscription.  

Cbd Öl, Cbd Oil, Hemp Oil, Oil, Cbd, Superfood, Hanf

Relevant Patent Documents

Patent US10603290  

Patent US10603288  


Z-ARCHIVE-Cannabis   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

For a blog.



301